GlobeNewswire·Mar 30, 2026, 7:48 AM ET

Eikon Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Clinical and Corporate Updates

EIKN

Eikon Therapeutics closed an upsized IPO in February 2026, raising $381.2 million in gross proceeds.
The company completed enrollment in the TeLuRide-005 Phase 2 trial for EIK1001 in combination with pembrolizumab & chemotherapy for first-line stage 4 non-small cell lung cancer treatment.
Comprehensive data from the EIK1001 Phase 2 study is expected in the second half of 2026.
EIK1003, a selective PARP1 inhibitor, is being evaluated in a Phase 1/2 trial, with Cohort 1D combining it with platinum & paclitaxel anticipated in the second half of 2026.
EIK1004, a PARP1 inhibitor capable of crossing the blood-brain barrier, is under evaluation in a Phase 1/2 trial for advanced solid tumors including those with brain metastases.
EIK1005, a WRN helicase inhibitor, successfully completed a healthy volunteer study in late 2025 & has initiated a Phase 1/2 trial in patients with malignant disease.
David W. Meline, former CFO of Moderna, was elected as an independent director in December 2025.
As of December 31, 2025, the company held $336.0 million in cash, cash equivalents, & marketable securities.
The company expects its cash position, including IPO proceeds, to fund operations into the second half of 2027.
R&D expenses totaled $250.3 million for 2025, a 22% increase driven by expanded clinical trials, new headquarters occupancy, & headcount growth.
G&A expenses reached $88.6 million for 2025, a 59% increase primarily due to $21.3 million in asset impairments, compensation costs, & depreciation from the new Millbrae headquarters.
Net loss attributable to common stockholders was $333.6 million for the full year 2025, compared to $243.8 million in 2024.